 | • レポートコード：MRC2305A056 • 出版社/出版日：Transparency Market Research / 2023年3月24日 • レポート形態：英文、PDF、164ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| トランスパレンシーマーケットリサーチ社の市場調査資料では、世界の脂質降下薬（LLD）市場規模が、2023年の314億ドルから2031年に425億ドルとなり、予測期間中にCAGR 3.4%で拡大すると見込んでいます。本資料は、脂質降下薬（LLD）の世界市場について市場実態を明らかにし、将来を展望したレポートであり、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、薬剤クラス別（スタチン・化合物、PCSK9阻害剤、胆汁酸封鎖剤、フィブラート、その他）分析、疾患別（高コレステロール血症、冠動脈疾患、高トリグリセリド血症）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを掲載しています。本書内には、Sanofi、Pfizer, Inc.、GlaxoSmithKline plc、Novartis AG、Merck & Co., Inc.、Amgen Inc.、Takeda Pharmaceutical Company Limited、Sun Pharmaceutical Industries Ltd.、AbbVie, Inc.、Viatris (Mylan N.V.)、AstraZeneca PLC、Dr. Reddy’s Laboratories Ltd.などの企業情報を含んでいます。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・世界の脂質降下薬（LLD）市場規模：薬剤クラス別 - スタチン・化合物の市場規模 - PCSK9阻害剤の市場規模 - 胆汁酸封鎖剤の市場規模 - フィブラートの市場規模 - その他薬剤クラスの市場規模 ・世界の脂質降下薬（LLD）市場規模：疾患別 - 高コレステロール血症における市場規模 - 冠動脈疾患における市場規模 - 高トリグリセリド血症における市場規模 ・世界の脂質降下薬（LLD）市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界の脂質降下薬（LLD）市場規模：地域別 - 北米の脂質降下薬（LLD）市場規模 - ヨーロッパの脂質降下薬（LLD）市場規模 - アジア太平洋の脂質降下薬（LLD）市場規模 - 中南米の脂質降下薬（LLD）市場規模 - 中東・アフリカの脂質降下薬（LLD）市場規模 ・競争状況 |
Lipid-lowering Drugs Market – Scope of Report
TMR’s report on the global lipid-lowering drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global lipid-lowering drugs market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lipid-lowering drugs market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the lipid-lowering drugs market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global lipid-lowering drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global lipid-lowering drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global lipid-lowering drugs market.
The report delves into the competitive landscape of the global lipid-lowering drugs market. Key players operating in the global lipid-lowering drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global lipid-lowering drugs market profiled in this report.
Key Questions Answered in Global Lipid-lowering Drugs Market Report
• What is the sales/revenue generated by lipid-lowering drugs across all regions during the forecast period?
• What are the opportunities in the global lipid-lowering drugs market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?
Lipid-lowering Drugs Market – Research Objectives and Research Approach
The comprehensive report on the global lipid-lowering drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global lipid-lowering drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global lipid-lowering drugs market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Lipid-lowering Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Lipid-lowering Drugs Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Drug Pipeline Analysis
5.2. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
5.3. Regulatory Scenario by Region/globally
5.4. Patent Analysis
6. Global Lipid-lowering Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017-2031
6.3.1. Statins & Combination
6.3.2. PCSK9 Inhibitors
6.3.3. Bile Acid Sequestrants
6.3.4. Fibrates
6.3.5. Cholesterol Absorption Inhibitors
6.3.6. Others
6.4. Market Attractiveness, by Drug Class
7. Global Lipid-lowering Drugs Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Indication, 2017-2031
7.3.1. Hypercholesterolemia
7.3.2. Coronary Artery Disease
7.3.3. High Triglycerides
7.4. Market Attractiveness, by Indication
8. Global Lipid-lowering Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017-2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness, by Distribution Channel
9. Global Lipid-lowering Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Country/Region
10. North America Lipid-lowering Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017-2031
10.2.1. Statins & Combination
10.2.2. PCSK9 Inhibitors
10.2.3. Bile Acid Sequestrants
10.2.4. Fibrates
10.2.5. Cholesterol Absorption Inhibitors
10.2.6. Others
10.3. Market Value Forecast, by Indication, 2017-2031
10.3.1. Hypercholesterolemia
10.3.2. Coronary Artery Disease
10.3.3. High Triglycerides
10.4. Market Value Forecast, by Distribution Channel, 2017-2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Indication
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Lipid-lowering Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017-2031
11.2.1. Statins & Combination
11.2.2. PCSK9 Inhibitors
11.2.3. Bile Acid Sequestrants
11.2.4. Fibrates
11.2.5. Cholesterol Absorption Inhibitors
11.2.6. Others
11.3. Market Value Forecast, by Indication, 2017-2031
11.3.1. Hypercholesterolemia
11.3.2. Coronary Artery Disease
11.3.3. High Triglycerides
11.4. Market Value Forecast, by Distribution Channel, 2017-2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Indication
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Lipid-lowering Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017-2031
12.2.1. Statins & Combination
12.2.2. PCSK9 Inhibitors
12.2.3. Bile Acid Sequestrants
12.2.4. Fibrates
12.2.5. Cholesterol Absorption Inhibitors
12.2.6. Others
12.3. Market Value Forecast, by Indication, 2017-2031
12.3.1. Hypercholesterolemia
12.3.2. Coronary Artery Disease
12.3.3. High Triglycerides
12.4. Market Value Forecast, by Distribution Channel, 2017-2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Indication
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Lipid-lowering Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017-2031
13.2.1. Statins & Combination
13.2.2. PCSK9 Inhibitors
13.2.3. Bile Acid Sequestrants
13.2.4. Fibrates
13.2.5. Cholesterol Absorption Inhibitors
13.2.6. Others
13.3. Market Value Forecast, by Indication, 2017-2031
13.3.1. Hypercholesterolemia
13.3.2. Coronary Artery Disease
13.3.3. High Triglycerides
13.4. Market Value Forecast, by Distribution Channel, 2017-2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast By Country/Sub-region, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Indication
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Lipid-lowering Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017-2031
14.2.1. Statins & Combination
14.2.2. PCSK9 Inhibitors
14.2.3. Bile Acid Sequestrants
14.2.4. Fibrates
14.2.5. Cholesterol Absorption Inhibitors
14.2.6. Others
14.3. Market Value Forecast, by Indication, 2017-2031
14.3.1. Hypercholesterolemia
14.3.2. Coronary Artery Disease
14.3.3. High Triglycerides
14.4. Market Value Forecast, by Distribution Channel, 2017-2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Indication
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share/Ranking Analysis By Company (2022)
15.3. Company Profiles
15.3.1. Sanofi
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Strategic Overview
15.3.2. Pfizer, Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Strategic Overview
15.3.3. GlaxoSmithKline plc
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Strategic Overview
15.3.4. Novartis AG
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Strategic Overview
15.3.5. Merck & Co., Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Strategic Overview
15.3.6. Amgen Inc.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Strategic Overview
15.3.7. Takeda Pharmaceutical Company Limited
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Strategic Overview
15.3.8. Sun Pharmaceutical Industries Ltd.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Strategic Overview
15.3.9. AbbVie, Inc.
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Strategic Overview
15.3.10. Viatris (Mylan N.V.)
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Strategic Overview
15.3.11. AstraZeneca PLC
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Strategic Overview
15.3.12. Dr. Reddy’s Laboratories Ltd.
15.3.12.1. Company Overview
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Strategic Overview
Table 01: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 02: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by 2017‒2031, by Indication
Table 03: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 07: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 08: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 10: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 11: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 12: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 15: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 16: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 18: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 19: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 20: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 23: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 24: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031